The State of Supplement Claims
No regulator approves a supplement claim before it goes live. The market runs on self-policing, so the only question that decides anything is who actually reads the copy. Until now, the answer was nobody. We read the best-selling listings in eight major Amazon US categories and ruled every phrase against all 98 standards in a full September 2026 re-scan: 1,524 listings, 587 brands, more than 149,000 phrase checks. 75% received an outright FAIL verdict, and 39% of the brands behind them carry at least one Critical finding, a named-condition or disease claim that fails 21 U.S.C. §343(r)(6) outright.
Method · every phrase ruled against FDA structure/function, FTC substantiation and marketplace policy · pharmacist-signed methodology · brands never named in public data · free to cite with attribution
Executive summary
Three in four top-selling supplement listings fail outright.
75% of the listings we ruled received a FAIL verdict against the published standards. These are not fringe products. They are the bestsellers in sleep, gut, stress, immune, cognitive, joint, sports and energy.
More than one in three supplement brands carries a claim that can take a listing down.
39% of scanned brands, 229 of 587, carry at least one Critical finding: a named-condition or disease claim that fails 21 U.S.C. §343(r)(6) outright and is enforceable on sight.
The single most common failure is also the cheapest to fix.
The number one finding in our scan data is not an exotic claim. It is a sentence that costs nothing to add: the FDA disclaimer, missing at 324 of the 587 brands. Close behind are an unsupported superlative (“best”, “most effective”) at 306 brands and a Non-GMO claim with no document behind it at 295. The industry’s most widespread compliance failures are a sentence that costs nothing, a word that needs support and a claim that needs a document.
These are not fringe products. They are the listings with the most revenue at stake, the most resources to get it right, and the most to lose when a marketplace switches them off. When three in four of those fail, the explanation is not that the industry is dishonest. It is that nobody was checking.
Method and data
Listings enter the database through the same engine that runs our paid audits. Each listing is ruled, phrase by phrase, against all 98 standards in the September 2026 re-scan, which is built on FDA structure/function rules, FTC substantiation guidance and Amazon’s supplement claims policy. These are rulings, not scraped copy: every phrase gets a verdict and a severity of Critical, High, Medium or Low. Automated rulings are reviewed by a person before they enter published figures, and paid audit verdicts are signed by a licensed pharmacist. Aggregate figures update as listings are added, and individual brands are never named in public data. The full method and the standards behind it are documented on the Standards page.
The nearest prior work measured what is inside the bottle rather than what the listing says. A 2023 JAMA analysis found 88% of melatonin products mislabeled. This report measures the other half of the package: the claims.
The verdict split
A FAIL verdict means the listing carries at least one Critical or High finding, a phrase that breaks a published standard seriously enough that the listing as a whole does not pass. FIX THEN PASS means the only findings were Medium or Low. PASS means no findings at all.
Every ruled listing by verdict · 1,524 listings
Failure is not the exception in this market, it is the median outcome. A FAIL verdict does not mean the product is unsafe or ineffective. This report measures marketing language, not chemistry. But marketing language is what regulators, platforms and courts actually read, and by that measure the majority of the category’s bestsellers do not hold up.
Percentages rounded to the nearest point. Counts are exact.
Fail rate by category
Compliance is not evenly distributed. Stress and gut and digestion are the lowest-compliance categories we scan, at 82% and 80% fail rates against 75% across all eight. Both invite condition-shaped language: stress and cortisol sit next to named anxiety disorders, digestion, bloating and regularity next to named GI conditions in a copywriter’s mind, and the listings show it.
The right-hand column is the share of that category’s brands carrying at least one Critical finding. Gut and digestion leads there, at 53% against 39% overall. Category rows count every listing ruled in that category, so they total 1,624 against 1,524 distinct listings: 100 listings sell into more than one category and are ruled in each.
Fail means at least one Critical or High finding on the live listing.
The phrase table
This is the centre of the report. If the failures were the work of a few bad actors inventing wild claims, the table below would be a long tail of oddities. It is not. It is ten phrases, repeated across hundreds of unconnected brands, ranked by how many carry each one. Struck phrases are quoted from live listings. The brands are not named. Their copy names them.
Counts are distinct brands, among the 587 ruled, that carry the phrase or a direct variant. Bars are scaled to the top row.
Two patterns here are worth naming. First, three of the top five findings are paperwork, not science: a required disclaimer that is missing, a Non-GMO claim with no document behind it, and a certification badge that cannot be verified from the listing. Second, the rest are the ordinary vocabulary of supplement marketing. “Best”, “boosts immunity” and “balances hormones” are not written by rogue copywriters. They are the default language of the category, and the default language fails.
Inside the findings
Across the 1,524 listings we logged 6,419 individual findings. Critical findings are the most dangerous: 615 of them, clustered in 229 brands rather than spread evenly across the 587.
Every finding logged, by severity · 6,419 findings
The dated record
The numbers above would matter less if enforcement were theoretical. It is not, and it has accelerated on several fronts.
Four institutions with four different incentives now read supplement listings the same way. The window where a risky phrase was somebody else’s problem has closed.
Sources: FTC penalty schedule and Notice of Penalty Offenses, FDA warning-letter database, Amazon seller policy, public litigation record.
Guidance
This is general information, not legal advice. The data does suggest a clear order of operations.
Fix the paperwork first.
The two most common failures in our scan data are paperwork, not language: a certification badge with no certificate behind it, and a missing FDA disclaimer, which is required alongside structure/function claims, costs nothing, and is absent at 324 brands.
Hunt named conditions.
More than one in three brands carries a claim that mentions or implies a disease. These are the findings that end listings and start lawsuits. Search your own copy for condition names, and for their synonyms and abbreviations, everywhere: product page, packaging renders, review responses, backend keywords.
Audit your certifications.
“GMP certified” appears on the listings of 226 brands. When the certification cannot be verified, the badge is itself a claim at risk. If you display it, be able to document it.
Treat default marketing language as suspect.
“Boosts immunity”, “clinically proven” and “balances hormones” read as normal because everyone uses them. Everyone using a phrase is not evidence that it is compliant. It is evidence that the fail rate is 75%.
Reread the detail page against the marketplace policy, not just the label.
Amazon prohibits disease and treatment claims on supplement detail pages under its Restricted Products policy, and that covers backend keywords as well as the copy a shopper reads. Most listings were written against the label alone.
Pharmacist-in-the-loop
Is your copy in this data?
The audit answers in five business days: every claim, every channel, pharmacist signed.
Cite this report
Citing this report
Every figure on this page is free to cite with attribution to “Claims Verified, The State of Supplement Claims, Q3 2026” and a link to claimsverified.org/research/state-of-claims/. Figures reflect the September 2026 database snapshot and update as scanning continues. For category-level breakdowns, methodology questions or interviews, email the research desk.
audit@claimsverified.org →Media and methodology questions: audit@claimsverified.org · © 2026 Claims Verified · Data from the claims database, snapshot 14 Sep 2026 · Reproduction with attribution permitted · Cite as “Claims Verified, State of Supplement Claims, Q3 2026” · Not legal advice